Literature DB >> 6705135

Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.

A G Bosanquet, E D Gilby.   

Abstract

Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2 = 10-12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the 'PO fed' and 'PO fasting' days: on the PO fed days the delay before absorption started was longer (1.1 +/- 0.5 h as against 0.3 +/- 0.1 h); peak plasma levels were one-third the value (65 +/- 15 ng/ml; 195 +/- 80 ng/ml) and occurred at twice the time after administration (2.8 +/- 0.8 h; 1.3 +/- 0.3 h); and areas under the curve were smaller 10.8 +/- 4.7 min X micrograms/ml; 23.8 +/- 13.8 min X micrograms/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49 +/- 0.20) and on the PO fasting day (0.93 +/- 0.22), with P less than 0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6705135     DOI: 10.1007/bf00256542

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.

Authors:  K W Woodhouse; P Hamilton; A Lennard; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Measurement of plasma melphalan at therapeutic concentrations using isocratic high-performance liquid chromatography.

Authors:  A G Bosanquet; E D Gilby
Journal:  J Chromatogr       Date:  1982-11-12

4.  Pharmacology of intravenous melphalan in patients with multiple myeloma.

Authors:  L Brox; L Birkett; A Belch
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

5.  Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Eur J Cancer Clin Oncol       Date:  1982-04

6.  Quantitation by gas chromatography-chemical ionization-mass spectrometry of phenylalanine mustard in plasma of patients.

Authors:  S L Pallante; C Fenselau; R G Mennel; R B Brundrett; M Appler; N B Rosenshein; M Colvin
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

7.  Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia?

Authors:  C R Pinkerton; S G Welshman; J F Glasgow; J M Bridges
Journal:  Lancet       Date:  1980-11-01       Impact factor: 79.321

8.  Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.

Authors:  I A Taha; R A Ahmad; H Gray; C I Roberts; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  An assessment of a short-term tumour chemosensitivity assay in chronic lymphocytic leukaemia.

Authors:  A G Bosanquet; M C Bird; W J Price; E D Gilby
Journal:  Br J Cancer       Date:  1983-06       Impact factor: 7.640

10.  Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.

Authors:  T J McElwain; D W Hedley; G Burton; H M Clink; M Y Gordon; M Jarman; C A Juttner; J L Millar; R A Milsted; G Prentice; I E Smith; D Spence; M Woods
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

View more
  19 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.

Authors:  U Loos; E Musch; M Engel; J H Hartlapp; E Hügl; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Effect of L-leucine on oral melphalan kinetics in patients.

Authors:  P A Reece; B M Dale; R G Morris; D Kotasek; D Gee; S Rogerson; R E Sage
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.

Authors:  J Ninane; R Baurain; A de Selys; A Trouet; G Cornu
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  The effect of dietary amino acids on the gastrointestinal absorption of melphalan and chlorambucil.

Authors:  C G Adair; J C McElnay
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases.

Authors:  C Ardiet; B Tranchand; P Biron; P Rebattu; T Philip
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  The effect of food on oral melphalan absorption.

Authors:  P A Reece; D Kotasek; R G Morris; B M Dale; R E Sage
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.